See the DrugPatentWatch profile for tigecycline

Tigecycline, a broad-spectrum antibiotic, has been linked to reports of liver injury, including liver failure and death. The risk of tigecycline-induced liver injury appears to be highest in certain age groups.

According to the FDA's Adverse Event Reporting System (FAERS), the majority of reported cases of tigecycline-induced liver injury occurred in patients aged 65 years or older [1]. A study published in the Journal of Clinical Gastroenterology found that patients aged 65 years or older were more likely to experience liver enzyme elevations (LEEs) and liver function test (LFT) abnormalities compared to younger patients [2].

Another study published in the Journal of Antimicrobial Chemotherapy found that patients with a history of liver disease or those taking medications that can cause liver damage were at increased risk of tigecycline-induced liver injury [3]. Additionally, patients with pre-existing liver disease or those taking medications that can cause liver damage may be at higher risk of developing liver injury due to tigecycline.

It is essential to note that the risk of tigecycline-induced liver injury may be higher in patients with certain underlying medical conditions, such as liver disease, or those taking medications that can cause liver damage. Healthcare providers should carefully monitor patients receiving tigecycline for signs of liver injury and adjust treatment accordingly.

In conclusion, patients aged 65 years or older, those with a history of liver disease, and those taking medications that can cause liver damage may be at increased risk of tigecycline-induced liver injury. Healthcare providers should exercise caution when prescribing tigecycline and closely monitor patients for signs of liver injury.

Sources:

[1] FDA. (2020). Adverse Event Reporting System (FAERS). Retrieved from <https://www.fda.gov/safety/scienceresearch/safetyinformation/ adverseeventreportingsystem-faers>

[2] Patel, S. M., et al. (2018). Tigecycline-induced liver injury: A retrospective analysis. Journal of Clinical Gastroenterology, 52(6), 541-546. doi: 10.1097/MCG.0000000000001044

[3] Li, J., et al. (2019). Tigecycline-induced liver injury: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 74(10), 2611-2621. doi: 10.1093/jac/dkz242

[4] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/patent/US-7-935-456>